258 related articles for article (PubMed ID: 35835862)
1. Relapse rates after withdrawal of thiopurines in patients with inflammatory bowel disease.
Ranjan MK; Vuyyuru SK; Kante B; Kumar P; Mundhra SK; Golla R; Sharma R; Sahni P; Das P; Makharia G; Kedia S; Ahuja V
Int J Colorectal Dis; 2022 Aug; 37(8):1817-1826. PubMed ID: 35835862
[TBL] [Abstract][Full Text] [Related]
2. Poor Drug Sustainability in Inflammatory Bowel Disease Patients in Clinical Remission on Thiopurine Monotherapy.
Balram B; Lubov J; Theoret Y; Afif W; Bitton A; Wild G; Lakatos PL; Bessissow T
Dig Dis Sci; 2021 May; 66(5):1650-1657. PubMed ID: 32591969
[TBL] [Abstract][Full Text] [Related]
3. Thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease: relapse and recapture rates, with predictive factors in 237 patients.
Kennedy NA; Kalla R; Warner B; Gambles CJ; Musy R; Reynolds S; Dattani R; Nayee H; Felwick R; Harris R; Marriott S; Senanayake SM; Lamb CA; Al-Hilou H; Gaya DR; Irving PM; Mansfield J; Parkes M; Ahmad T; Cummings JR; Arnott ID; Satsangi J; Lobo AJ; Smith M; Lindsay JO; Lees CW
Aliment Pharmacol Ther; 2014 Dec; 40(11-12):1313-23. PubMed ID: 25284134
[TBL] [Abstract][Full Text] [Related]
4. Thiopurine monotherapy is effective in ulcerative colitis but significantly less so in Crohn's disease: long-term outcomes for 11 928 patients in the UK inflammatory bowel disease bioresource.
Stournaras E; Qian W; Pappas A; Hong YY; Shawky R; ; Raine T; Parkes M;
Gut; 2021 Apr; 70(4):677-686. PubMed ID: 33004550
[TBL] [Abstract][Full Text] [Related]
5. Minimal risk of lymphoma and non-melanoma skin cancer despite long-term use of thiopurines in patients with inflammatory bowel disease: A longitudinal cohort analysis from northern India.
Ranjan MK; Kante B; Vuyyuru SK; Kumar P; Mundhra SK; Golla R; Sharma R; Sahni P; Das P; Makharia G; Kedia S; Ahuja V
J Gastroenterol Hepatol; 2022 Aug; 37(8):1544-1553. PubMed ID: 35501287
[TBL] [Abstract][Full Text] [Related]
6. Do Thiopurines Reduce the Risk of Surgery in Elderly Onset Inflammatory Bowel Disease? A 20-Year National Population-Based Cohort Study.
Alexakis C; Saxena S; Chhaya V; Cecil E; Curcin V; Pollok R
Inflamm Bowel Dis; 2017 Apr; 23(4):672-680. PubMed ID: 28151735
[TBL] [Abstract][Full Text] [Related]
7. Thiopurines Have Sustained Long-term Effectiveness in Patients with Inflammatory Bowel Disease, Which is Independent of Disease Duration at Initiation: A Propensity Score Matched Analysis.
Ranjan MK; Kumar P; Vuyyuru SK; Kante B; Mundhra SK; Golla R; Virmani S; Sharma R; Sahni P; Das P; Kalaivani M; Upadhyay AD; Makharia G; Kedia S; Ahuja V
J Crohns Colitis; 2024 Feb; 18(2):192-203. PubMed ID: 37584328
[TBL] [Abstract][Full Text] [Related]
8. Thiopurine Monotherapy Is Effective in Maintenance of Mild-Moderate Inflammatory Bowel Disease.
Barber GE; Hendler S; Choe M; Keyashian K; Lechner S; Limketkai BN; Limsui D
Dig Dis Sci; 2022 Apr; 67(4):1287-1294. PubMed ID: 33755823
[TBL] [Abstract][Full Text] [Related]
9. Complete Endoscopic Healing Is Associated With Lower Relapse Risk After Anti-TNF Withdrawal in Inflammatory Bowel Disease.
Mahmoud R; Savelkoul EHJ; Mares W; Goetgebuer R; Witteman BJM; de Koning DB; van Tuyl SAC; Minderhoud I; Lutgens MWMD; Akol-Simsek D; van Schaik FDM; Fidder HH; Jansen JM; van Boeckel PGA; Mahmmod N; Horjus-Talabur Horje CS; Römkens TEH; Colombel JF; Hoentjen F; Jharap B; Oldenburg B;
Clin Gastroenterol Hepatol; 2023 Mar; 21(3):750-760.e4. PubMed ID: 36055567
[TBL] [Abstract][Full Text] [Related]
10. Azathioprine monotherapy withdrawal in inflammatory bowel diseases: A retrospective mono-centric study.
Crepaldi M; Maniero D; Massano A; Pavanato M; Barberio B; Savarino EV; Zingone F
World J Gastroenterol; 2023 Jul; 29(27):4334-4343. PubMed ID: 37545640
[TBL] [Abstract][Full Text] [Related]
11. Withdrawal of Azathioprine in Inflammatory Bowel Disease Patients Who Sustain Remission: New Risk Factors for Relapse.
Iborra M; Herreras J; Boscá-Watts MM; Cortés X; Trejo G; Cerrillo E; Hervás D; Mínguez M; Beltrán B; Nos P
Dig Dis Sci; 2019 Jun; 64(6):1612-1621. PubMed ID: 30604371
[TBL] [Abstract][Full Text] [Related]
12. Systematic Review of Effects of Withdrawal of Immunomodulators or Biologic Agents From Patients With Inflammatory Bowel Disease.
Torres J; Boyapati RK; Kennedy NA; Louis E; Colombel JF; Satsangi J
Gastroenterology; 2015 Dec; 149(7):1716-30. PubMed ID: 26381892
[TBL] [Abstract][Full Text] [Related]
13. Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study.
Casanova MJ; Chaparro M; García-Sánchez V; Nantes O; Leo E; Rojas-Feria M; Jauregui-Amezaga A; García-López S; Huguet JM; Arguelles-Arias F; Aicart M; Marín-Jiménez I; Gómez-García M; Muñoz F; Esteve M; Bujanda L; Cortés X; Tosca J; Pineda JR; Mañosa M; Llaó J; Guardiola J; Pérez-Martínez I; Muñoz C; González-Lama Y; Hinojosa J; Vázquez JM; Martinez-Montiel MP; Rodríguez GE; Pajares R; García-Sepulcre MF; Hernández-Martínez A; Pérez-Calle JL; Beltrán B; Busquets D; Ramos L; Bermejo F; Barrio J; Barreiro-de Acosta M; Roncedo O; Calvet X; Hervías D; Gomollón F; Domínguez-Antonaya M; Alcaín G; Sicilia B; Dueñas C; Gutiérrez A; Lorente-Poyatos R; Domínguez M; Khorrami S; Muñoz C; Taxonera C; Rodríguez-Pérez A; Ponferrada A; Van Domselaar M; Arias-Rivera ML; Merino O; Castro E; Marrero JM; Martín-Arranz M; Botella B; Fernández-Salazar L; Monfort D; Opio V; García-Herola A; Menacho M; Ramírez-de la Piscina P; Ceballos D; Almela P; Navarro-Llavat M; Robles-Alonso V; Vega-López AB; Moraleja I; Novella MT; Castaño-Milla C; Sánchez-Torres A; Benítez JM; Rodríguez C; Castro L; Garrido E; Domènech E; García-Planella E; Gisbert JP
Am J Gastroenterol; 2017 Jan; 112(1):120-131. PubMed ID: 27958281
[TBL] [Abstract][Full Text] [Related]
14. Long-term Safety and Efficacy of Low-dose Azathioprine and Allopurinol Cotherapy in Inflammatory Bowel Disease: A Large Observational Study.
Pavlidis P; Stamoulos P; Abdulrehman A; Kerr P; Bull C; Duley J; Ansari A
Inflamm Bowel Dis; 2016 Jul; 22(7):1639-46. PubMed ID: 27271488
[TBL] [Abstract][Full Text] [Related]
15. The drug-survival of low-dose thioguanine in patients with inflammatory bowel disease: a retrospective observational study.
Gensmyr-Singer H; Werner M; Karling P
Therap Adv Gastroenterol; 2024; 17():17562848241228064. PubMed ID: 38384282
[TBL] [Abstract][Full Text] [Related]
16. Risk of lymphoma in patients with ulcerative colitis treated with thiopurines: a nationwide retrospective cohort study.
Khan N; Abbas AM; Lichtenstein GR; Loftus EV; Bazzano LA
Gastroenterology; 2013 Nov; 145(5):1007-1015.e3. PubMed ID: 23891975
[TBL] [Abstract][Full Text] [Related]
17. Long-term clinical outcome after thiopurine discontinuation in elderly IBD patients.
Jorissen C; Verstockt B; Schils N; Sabino J; Ferrante M; Vermeire S
Scand J Gastroenterol; 2021 Nov; 56(11):1323-1327. PubMed ID: 34399630
[TBL] [Abstract][Full Text] [Related]
18. A trial of mercaptopurine is a safe strategy in patients with inflammatory bowel disease intolerant to azathioprine: an observational study, systematic review and meta-analysis.
Kennedy NA; Rhatigan E; Arnott ID; Noble CL; Shand AG; Satsangi J; Lees CW
Aliment Pharmacol Ther; 2013 Nov; 38(10):1255-66. PubMed ID: 24117596
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis.
Khan KJ; Dubinsky MC; Ford AC; Ullman TA; Talley NJ; Moayyedi P
Am J Gastroenterol; 2011 Apr; 106(4):630-42. PubMed ID: 21407186
[TBL] [Abstract][Full Text] [Related]
20. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review.
Fraser AG; Orchard TR; Jewell DP
Gut; 2002 Apr; 50(4):485-9. PubMed ID: 11889067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
